The Stockholm Uppsala Life Science Cluster is a globally recognized hub for advanced therapy medicinal products (ATMPs) and biomanufacturing. This region, encompassing major facilities in Stockholm, Uppsala, Södertälje, Strängnäs, and Solna, is renowned for its pioneering research, strong academic-industry collaborations, and significant contributions to the global biopharmaceutical market. With a robust infrastructure, extensive biobanks, and a supportive government, the cluster is at the forefront of life science innovation, making it an ideal location for companies looking to establish and expand their biomanufacturing capabilities.
Among the key players in this vibrant ecosystem is NorthX Biologics, which leverages cutting-edge technologies and extensive expertise to drive advancements in ATMPs. Supported by strategic government investments and a network of universities, hospitals, and life science companies, NorthX Biologics contributes to the region’s reputation as a leader in life science innovation. This document provides an in-depth look at the region’s strengths, key players, and the collaborative efforts driving its success in the life sciences sector.
Read the full article here.
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
The complex journey of bringing a biologic to market – part 2 The journey from early development to commercial production in biologics is paved with complexity and few phases are ...
The complex journey of bringing a biologic to market – part 1 Biologic drugs differ from traditional medicines as they are produced in living systems, making their development and manufacturing ...
In an increasingly unstable world, Sweden is taking decisive steps to secure access to critical pharmaceuticals during crises and war. As part of a broader government initiative, highlighted in a ...